Related Experiment Video
Updated: Apr 12, 2026
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Trends in survival for patients with metastatic breast cancer: is survival improving?
Jacopo Giuliani1, Andrea Bonetti
1Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Legnago (Verona) - Italy.
Introduction:
The treatment of patients with metastatic breast cancer (mBC) is one of the most difficult problems in clinical oncology. Clinical trial results suggest that novel therapies may be having a favorable impact on the survival of mBC patients, but the real impact of new therapies on OS rates has yet to be established. The aim of this outcome study was to evaluate the most reliable parameters to define the long-term result in terms of OS of different treatment strategies for mBC patients in a real-world clinical practice.
Materials And Methods:
A retrospective analysis of consecutive patients diagnosed with mBC between February 2001 and December 2008 and treated at our medical oncology unit was performed.
Results:
We evaluated 70 female patients. At the last follow-up all patients had died. Median OS was 31.55 months (range, 2.33-100.13). There was no statistically significant difference in OS (p = 0.284) between the period 2001-2004 and the period 2005-2008. We did not find any statistically significant difference in OS even in the transition from one year to the next (p = 0.154).
Conclusions:
The results of the current analysis suggest that the OS of women with mBC has not improved in the last years. However, these results should be interpreted with caution, considering the difficulty of determining changes in survival over time. Larger studies are needed to corroborate our findings.
Insights
This study found no significant improvement in overall survival (OS) for metastatic breast cancer (mBC) patients despite new therapies. Real-world data suggests current treatment strategies may not be enhancing long-term outcomes for mBC patients.
Area of Science:
- Oncology
- Clinical Medicine
- Epidemiology
Background:
- Metastatic breast cancer (mBC) presents significant challenges in clinical oncology.
- While novel therapies show promise in clinical trials, their real-world impact on overall survival (OS) for mBC patients remains unclear.
- Evaluating long-term OS outcomes in real-world practice is crucial for understanding treatment efficacy.
Purpose of the Study:
- To assess the real-world impact of different treatment strategies on the overall survival (OS) of metastatic breast cancer (mBC) patients.
- To identify reliable parameters for defining long-term outcomes in mBC treatment.
- To evaluate changes in OS rates over time in a clinical setting.
Main Methods:
- Retrospective analysis of metastatic breast cancer (mBC) patients.
- Data collected from patients diagnosed and treated between February 2001 and December 2008.
- Evaluation of overall survival (OS) based on treatment periods and year-to-year transitions.
Main Results:
- The study included 70 female patients with metastatic breast cancer (mBC).
- Median overall survival (OS) was 31.55 months.
- No statistically significant difference in OS was observed between treatment periods (2001-2004 vs. 2005-2008) or year-to-year.
Conclusions:
- Current real-world data suggests that overall survival (OS) for women with metastatic breast cancer (mBC) has not improved in recent years.
- These findings should be interpreted cautiously due to the complexities in determining survival changes over time.
- Larger studies are necessary to confirm these observations regarding mBC treatment outcomes.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
09:44Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
Related Concept Videos
01:21Cancer Survival Analysis
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:24Kaplan-Meier Approach